Suven Life Sciences Limited (SUVEN) — share transfer | 8 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Suven Life Sciences received a SEBI-mandated share transfer agent certificate for the quarter ended June 30, 2026, confirming compliance with dematerialization/rematerialization reporting requirements under Regulation 74(5). The filing includes duplicate certificates from Kfin Technologies Limited addressed to BSE and NSE exchanges, with no material changes or forward-looking statements disclosed.

📄 View Original Announcement (PDF)

About Suven Life Sciences Limited (SUVEN)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹11,087.76 Cr ROE: -80.9% ROCE: -80.7%

View full SUVEN stock details →

📡 Get AI alerts when SUVEN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUVEN — Free

📊 More SUVEN filings

See all SUVEN filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUVEN files new disclosures

Track SUVEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUVEN — Free

Free account · 2 AI queries/day